Sema4

Company profile

About Sema4

GeneDx, operating under the Sema4 brand, is a leading precision medicine and genomics company specializing in advanced genetic testing for rare and inherited diseases. The company provides comprehensive genomic testing solutions including whole exome sequencing (ExomeDx™), whole genome sequencing (GenomeDx™), rapid and ultrarapid testing, and targeted panels. Recognized as the #1 genetic test by pediatric and genetic specialists, GeneDx has performed over 2.5 million genetic tests, including nearly 1 million exomes and genomes sequenced, creating one of the largest rare disease datasets in the world—GeneDx Infinity™. The company serves multiple stakeholders including healthcare providers, patients and families, health systems, and biopharma companies. GeneDx's testing covers a wide range of conditions including neurodevelopmental disorders, epilepsy, autism spectrum disorder, cerebral palsy, congenital heart disease, global developmental delay, intellectual disability, inborn errors of immunity, and neonatal/pediatric critical care. The company's diagnostic approach analyzes approximately 20,000 genes and delivers diagnostic yields 17% greater than standard testing, with results available within days or weeks. GeneDx is an in-network provider for 79% of commercially insured patients across the U.S. and offers Medicaid coverage in 36 states, along with a Financial Assistance Program to reduce out-of-pocket costs. The company's GeneDx Infinity™ dataset, comprising 2.5+ million genetic tests and 8 million phenotypic data points, fuels AI-driven insights and enables precision medicine approaches for both clinical diagnosis and drug discovery.

Company description · Sema4 official website